September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched ...
TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house ...
TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data ...
Takeda presents orexin data from landmark oveporexton phase 3 programme in narcolepsy type 1 at World Sleep 2025: Singapore Tuesday, September 9, 2025, 13:00 Hrs [IST] Takeda will ...
Most recently, the Phase III pivotal clinical trial results of Fazamorexant, a first-class innovative anti-insomnia drug ...
MedPage Today on MSN
Novel Drug Fails to Outperform Common Treatment in Depression and Insomnia
An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an ...
Switzerland-based Idorsia announced that its licensee Simcere Pharmaceuticals has launched Quviviq (daridorexant), a dual ...
Allschwil, Switzerland - September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, "Simcere") has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback